Loading...
•
Dec 31, 2021
Ironwood Pharmaceuticals Q4 2021 Earnings Report
Reported fourth quarter and full year 2021 results, with LINZESS® achieving blockbuster status.
Key Takeaways
Ironwood Pharmaceuticals reported strong Q4 2021 results, driven by the success of LINZESS® which achieved blockbuster status with over $1 billion in U.S. net sales for the year. The company is also advancing its GI pipeline with clinical studies for IW-3300 and CNP-104.
LINZESS® achieved blockbuster status with over $1 billion in U.S. net sales in 2021.
Initiated clinical studies for IW-3300 for visceral pain conditions.
Initiated clinical study for CNP-104 for primary biliary cholangitis (PBC).
Company focuses on maximizing LINZESS growth and strengthening the GI pipeline.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood anticipates continued growth for LINZESS and aims to strengthen its GI pipeline while delivering sustained profits and generating cash flow.
Positive Outlook
- Maximizing LINZESS growth via commercial innovation and lifecycle management.
- Strengthening innovative GI pipeline.
- Delivering sustained profits.
- Generating cash flow.
- Advancing the treatment of GI diseases.
Challenges Ahead
- Effectiveness of development and commercialization efforts by Ironwood and its partners.
- Preclinical and clinical development, manufacturing and formulation development of linaclotide, CNP-104 and Ironwood's product candidates.
- Risk that clinical programs and studies may not progress or develop as anticipated.
- Risk that Ironwood or its partners are unable to obtain, maintain or manufacture sufficient LINZESS or product candidates.
- Efficacy, safety and tolerability of linaclotide and Ironwood's product candidates.